Schedule 13G Page 1 of 4
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. )*
---
Introgen Therapeutics, Inc.
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, $0.001 par value
--------------------------------------------------------------------------------
(Title of Class of Securities)
46119F 10 7
--------------------------------------------------------------------------------
(CUSIP Number)
December 31, 2001
--------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[ ] Rule 13d-1(b)
[ ] Rule 13d-1(c)
[X] Rule 13d-1(d)
Schedule 13G Page 2 of 4
CUSIP No. 46119F 10 7
--------------------------------------------------------------------------------
1. Names of Reporting Persons. I.R.S. Identification Nos. of above
persons (entities only).
David G. Nance
--------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group (See Instructions)
(a) [ ]
(b) [ ]
--------------------------------------------------------------------------------
3. SEC Use Only
--------------------------------------------------------------------------------
4. Citizenship or Place of Organization United States citizen
--------------------------------------------------------------------------------
Number of
Shares 5. Sole Voting Power 2,540,698
Beneficially
Owned by -------------------------------------------------------------
Each 6. Shared Voting Power 0
Reporting
Person With -------------------------------------------------------------
7. Sole Dispositive Power 2,540,698
-------------------------------------------------------------
8. Shared Dispositive Power 0
--------------------------------------------------------------------------------
9. Aggregate Amount Beneficially Owned by Each Reporting Person 2,540,698
--------------------------------------------------------------------------------
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
Instructions)
--------------------------------------------------------------------------------
11. Percent of Class Represented by Amount in Row (9) 11.8%
--------------------------------------------------------------------------------
12. Type of Reporting Person (See Instructions)
IN
--------------------------------------------------------------------------------
Schedule 13G Page 3 of 4
ITEM 1.
(a) Introgen Therapeutics, Inc., a Delaware corporation
(b) 301 Congress Ave., Suite 1850, Austin, TX 78701
ITEM 2.
(a) David G. Nance
(b) 301 Congress Ave., Suite 1850, Austin, TX 78701
(c) USA
(d) Common Stock, par value $0.001 per share
(e) 46119F 10 7
ITEM 3. NOT APPLICABLE
ITEM 4. OWNERSHIP
Provide the following information regarding the aggregate number and percentage
of the class of securities of the issuer identified in Item 1.
(a) Amount beneficially owed: 2,540,698
(b) Percent of class: 11.8%
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote 2,540,698
(ii) Shared power to vote or to direct the vote 0
(iii) Sole power to dispose or to direct the disposition of
2,540,698
(iv) Shared power to dispose or to direct the disposition
of 0
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
NOT APPLICABLE
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
Reporting Person has the right to receive and the power to direct the receipt of
dividends from or the proceeds from the sale of 2,215,605 shares by virtue of
his position as the Chief Executive Officer and sole stockholder of each of
Developtech Resources Corporation, Debouchement, Ltd. and Domecq Technologies,
Inc.
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE
SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY
NOT APPLICABLE
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
NOT APPLICABLE
ITEM 9. NOTICE OF DISSOLUTION OF GROUP
NOT APPLICABLE
Schedule 13G Page 4 of 4
ITEM 10. CERTIFICATION
(a) Not applicable.
(b) Not applicable
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
February 12, 2002
---------------------------------------
Date
/s/ DAVID G. NANCE
---------------------------------------
Signature
DAVID G. NANCE
---------------------------------------
Name/Title
ATTENTION: INTENTIONAL MISSTATEMENTS OR OMISSIONS OF FACT CONSTITUTE FEDERAL
CRIMINAL VIOLATIONS (SEE 18 U.S.C. 1001)